{"transactions":[{"id":751579,"issuer":{"id":5813,"kind":"organization","name":"DiaMedica Therapeutics Inc."},"owners":[{"id":41714,"kind":"person","name":"Lewis Tanya","position":1,"cik":"0001451038","reported_name":"Lewis Tanya","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-06-03T21:26:55.000Z","date":"2026-06-01","kind":"grant","planned":false,"acquired":true,"shares":40412,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Scheduled to vest in four equal quarterly installments."}],"balance_after":40412,"derivative":{"exercise_price":5.84,"expiration_date":"2036-06-01","underlying":"Voting Common Shares","underlying_shares":40412},"source":{"system":"sec-edgar","filing":"0001451038-26-000002","document":"form4-06032026_090650.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1451038/000145103826000002/form4-06032026_090650.xml","form_type":"4"}},{"id":1124739,"issuer":{"id":5813,"kind":"organization","name":"DiaMedica Therapeutics Inc."},"owners":[{"id":41714,"kind":"person","name":"Lewis Tanya","position":1,"cik":"0001451038","reported_name":"Lewis Tanya","relationship":{"director":true}}],"security":"Stock Option (right to buy)","published_at":"2025-06-03T20:17:10.000Z","date":"2025-06-01","kind":"grant","planned":false,"acquired":true,"shares":32162,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Vests in four nearly equal quarterly installments over one year."}],"balance_after":32162,"derivative":{"exercise_price":4.11,"expiration_date":"2035-05-31","underlying":"Common Shares","underlying_shares":32162},"source":{"system":"sec-edgar","filing":"0001437749-25-019292","document":"rdgdoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1451038/000143774925019292/rdgdoc.xml","form_type":"4"}},{"id":1495012,"issuer":{"id":5813,"kind":"organization","name":"DiaMedica Therapeutics Inc."},"owners":[{"id":41714,"kind":"person","name":"Lewis Tanya","position":1,"cik":"0001451038","reported_name":"Lewis Tanya","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-06-03T20:14:56.000Z","date":"2024-06-01","kind":"grant","planned":false,"acquired":true,"shares":28472,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Vests in four nearly equal quarterly installments over one year."}],"balance_after":28472,"derivative":{"exercise_price":2.9,"expiration_date":"2034-05-31","underlying":"Common Shares","underlying_shares":28472},"source":{"system":"sec-edgar","filing":"0001235802-24-000046","document":"primary_doc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1451038/000123580224000046/primary_doc.xml","form_type":"4"}},{"id":1854223,"issuer":{"id":4707,"kind":"organization","name":"Replimune Group, Inc."},"owners":[{"id":41714,"kind":"person","name":"Lewis Tanya","position":1,"cik":"0001451038","reported_name":"Lewis Tanya","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Dev. Op. Officer"}}],"security":"Common Stock","published_at":"2023-06-16T01:01:04.000Z","date":"2023-06-13","kind":"sale","planned":true,"acquired":false,"shares":817,"price":23.45,"value":19158.65,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 were made by the reporting person pursuant to a trading plan adopted on March 15, 2023, that is intended to comply with Rule 10b5-1(c) under the Securities Exchange Act of 1934, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported reflects a weighted average price. These shares were sold in multiple transactions at prices ranging from $23.34 to $23.55. The Reporting Person will provide to the Issuer, any security holder of the Issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F4","text":"Following the sales reported on this form 4, the reporting person continues to beneficially own 135,293 shares of the Issuer's common stock. The reporting person also holds options to acquire an aggregate of 248,750 shares of the Issuer's common stock, 80,259 of which are exercisable as of the date hereof."}],"balance_after":135293,"source":{"system":"sec-edgar","filing":"0001104659-23-071774","document":"tm2318878-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1451038/000110465923071774/tm2318878-2_4seq1.xml","form_type":"4"}},{"id":1854222,"issuer":{"id":4707,"kind":"organization","name":"Replimune Group, Inc."},"owners":[{"id":41714,"kind":"person","name":"Lewis Tanya","position":1,"cik":"0001451038","reported_name":"Lewis Tanya","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Dev. Op. Officer"}}],"security":"Common Stock","published_at":"2023-06-16T01:01:04.000Z","date":"2023-06-13","kind":"sale","planned":true,"acquired":false,"shares":12043,"price":24.1,"value":290236.3,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 were made by the reporting person pursuant to a trading plan adopted on March 15, 2023, that is intended to comply with Rule 10b5-1(c) under the Securities Exchange Act of 1934, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported reflects a weighted average price. These shares were sold in multiple transactions at prices ranging from $23.59 to $24.57. The Reporting Person will provide to the Issuer, any security holder of the Issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":136110,"source":{"system":"sec-edgar","filing":"0001104659-23-071774","document":"tm2318878-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1451038/000110465923071774/tm2318878-2_4seq1.xml","form_type":"4"}},{"id":1869570,"issuer":{"id":5813,"kind":"organization","name":"DiaMedica Therapeutics Inc."},"owners":[{"id":41714,"kind":"person","name":"Lewis Tanya","position":1,"cik":"0001451038","reported_name":"Lewis Tanya","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2023-06-02T20:13:39.000Z","date":"2023-06-01","kind":"grant","planned":false,"acquired":true,"shares":7493,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Vests in four nearly equal quarterly installments over one year."}],"balance_after":7493,"derivative":{"exercise_price":2.73,"expiration_date":"2033-05-31","underlying":"Common Shares","underlying_shares":7493},"source":{"system":"sec-edgar","filing":"0001235802-23-000057","document":"primary_doc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1451038/000123580223000057/primary_doc.xml","form_type":"4"}},{"id":1886765,"issuer":{"id":4707,"kind":"organization","name":"Replimune Group, Inc."},"owners":[{"id":41714,"kind":"person","name":"Lewis Tanya","position":1,"cik":"0001451038","reported_name":"Lewis Tanya","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Dev. Op. Officer"}}],"security":"Common Stock","published_at":"2023-05-19T00:34:34.000Z","date":"2023-05-16","kind":"sale","planned":false,"acquired":false,"shares":12207,"price":18.05,"value":220336.35,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares of the Issuer's common stock sold to cover tax withholding obligations in connection with the partial vesting of the Reporting Person's Restricted Stock Units (\"RSU\"). The transaction reported herein was made in accordance with the irrevocable \"sell to cover\" provision set forth in the award agreement under which the RSU was granted and does not represent a discretionary sale by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported reflects a weighted average price. These shares were sold in multiple transactions at prices ranging from $18.05 to $18.23. The Reporting Person will provide to the Issuer, any security holder of the Issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":148153,"source":{"system":"sec-edgar","filing":"0001104659-23-062376","document":"tm2316199-7_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1451038/000110465923062376/tm2316199-7_4seq1.xml","form_type":"4"}},{"id":1927898,"issuer":{"id":4707,"kind":"organization","name":"Replimune Group, Inc."},"owners":[{"id":41714,"kind":"person","name":"Lewis Tanya","position":1,"cik":"0001451038","reported_name":"Lewis Tanya","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Dev. Op. Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2023-04-05T00:01:20.000Z","date":"2023-04-01","kind":"grant","planned":false,"acquired":true,"shares":60000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"25% of the shares underlying this stock option vest on April 1, 2024, and the remainder of the shares underlying this stock option vest in 36 approximately equal monthly installments thereafter."}],"balance_after":60000,"derivative":{"exercise_price":17.66,"expiration_date":"2033-04-01","underlying":"Common Stock","underlying_shares":60000},"source":{"system":"sec-edgar","filing":"0001104659-23-041720","document":"tm2311410-4_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1451038/000110465923041720/tm2311410-4_4seq1.xml","form_type":"4"}},{"id":1927897,"issuer":{"id":4707,"kind":"organization","name":"Replimune Group, Inc."},"owners":[{"id":41714,"kind":"person","name":"Lewis Tanya","position":1,"cik":"0001451038","reported_name":"Lewis Tanya","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Dev. Op. Officer"}}],"security":"Common Stock","published_at":"2023-04-05T00:01:20.000Z","date":"2023-04-01","kind":"grant","planned":false,"acquired":true,"shares":40000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares of the Issuer's common stock issuable upon settlement of restricted stock units (\"RSUs\") granted to the Reporting Person. Each RSU represents a contingent right to receive one share of the Issuer's common stock. 25% of the RSUs will vest on May 15, 2024 and the remainder will vest in three approximately equal annual installments thereafter until May 15, 2027, subject to the Reporting Person's continuous service to the Issuer."}],"balance_after":160360,"source":{"system":"sec-edgar","filing":"0001104659-23-041720","document":"tm2311410-4_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1451038/000110465923041720/tm2311410-4_4seq1.xml","form_type":"4"}},{"id":1968903,"issuer":{"id":5813,"kind":"organization","name":"DiaMedica Therapeutics Inc."},"owners":[{"id":41714,"kind":"person","name":"Lewis Tanya","position":1,"cik":"0001451038","reported_name":"Lewis Tanya","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock option (right to buy)","published_at":"2023-03-06T22:14:02.000Z","date":"2023-03-01","kind":"grant","acquired":true,"shares":26443,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Vests in 12 nearly equal quarterly installments over three years."}],"balance_after":26443,"derivative":{"exercise_price":1.77,"expiration_date":"2033-02-28","underlying":"Common Shares","underlying_shares":26443},"source":{"system":"sec-edgar","filing":"0001235802-23-000029","document":"primary_doc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1451038/000123580223000029/primary_doc.xml","form_type":"4"}},{"id":2265576,"issuer":{"id":4707,"kind":"organization","name":"Replimune Group, Inc."},"owners":[{"id":41714,"kind":"person","name":"Lewis Tanya","position":1,"cik":"0001451038","reported_name":"Lewis Tanya","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Dev. Op Officer"}}],"security":"Common Stock","published_at":"2022-05-18T23:02:27.000Z","date":"2022-05-16","kind":"sale","acquired":false,"shares":5473,"price":14.59,"value":79851.07,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares of the Issuer's common stock sold to cover tax withholding obligations in connection with the partial vesting of the Reporting Person's Restricted Stock Units (\"RSU\"). The transaction reported herein was made in accordance with the irrevocable \"sell to cover\" provision set forth in the award agreement under which the RSU was granted and does not represent a discretionary sale by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported reflects a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.59 to $14.62. The Reporting Person will provide to the Issuer, any security holder of the Issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":120360,"source":{"system":"sec-edgar","filing":"0001104659-22-062608","document":"tm2215879-5_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1451038/000110465922062608/tm2215879-5_4seq1.xml","form_type":"4"}},{"id":2304203,"issuer":{"id":4707,"kind":"organization","name":"Replimune Group, Inc."},"owners":[{"id":41714,"kind":"person","name":"Lewis Tanya","position":1,"cik":"0001451038","reported_name":"Lewis Tanya","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Dev.Op Off"}}],"security":"Employee Stock Option (right to buy)","published_at":"2022-04-05T20:15:49.000Z","date":"2022-04-01","kind":"grant","acquired":true,"shares":78750,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"25% of the shares underlying this stock option vest on April 1, 2023, and the remainder of the shares underlying this stock option vest in 36 approximately equal monthly installments thereafter."}],"balance_after":78750,"derivative":{"exercise_price":18.26,"expiration_date":"2032-04-01","underlying":"Common Stock","underlying_shares":78750},"source":{"system":"sec-edgar","filing":"0001104659-22-042765","document":"tm2211665-5_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1451038/000110465922042765/tm2211665-5_4seq1.xml","form_type":"4"}},{"id":2304202,"issuer":{"id":4707,"kind":"organization","name":"Replimune Group, Inc."},"owners":[{"id":41714,"kind":"person","name":"Lewis Tanya","position":1,"cik":"0001451038","reported_name":"Lewis Tanya","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Dev.Op Off"}}],"security":"Common Stock","published_at":"2022-04-05T20:15:49.000Z","date":"2022-04-01","kind":"grant","acquired":true,"shares":52500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares of the Issuer's common stock issuable upon settlement of restricted stock units (\"RSUs\") granted to the Reporting Person. Each RSU represents a contingent right to receive one share of the Issuer's common stock. 25% of the RSUs will vest on May 15, 2023 and the remainder will vest in three approximately equal annual installments thereafter until May 15, 2026, subject to the Reporting Person's continuous service to the Issuer."}],"balance_after":125833,"source":{"system":"sec-edgar","filing":"0001104659-22-042765","document":"tm2211665-5_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1451038/000110465922042765/tm2211665-5_4seq1.xml","form_type":"4"}},{"id":2718489,"issuer":{"id":4707,"kind":"organization","name":"Replimune Group, Inc."},"owners":[{"id":41714,"kind":"person","name":"Lewis Tanya","position":1,"cik":"0001451038","reported_name":"Lewis Tanya","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Dev. Oper. Off."}}],"security":"Employee Stock Option (right to buy)","published_at":"2021-05-12T01:01:29.000Z","date":"2021-05-10","kind":"grant","acquired":true,"shares":110000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"25% of the shares underlying this stock option vest on May 10, 2022, and the remainder of the shares underlying this stock option vest in 36 approximately equal monthly installments thereafter."}],"balance_after":110000,"derivative":{"exercise_price":33.99,"expiration_date":"2031-05-10","underlying":"Common Stock","underlying_shares":110000},"source":{"system":"sec-edgar","filing":"0001104659-21-064730","document":"tm2115949-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1451038/000110465921064730/tm2115949-1_4seq1.xml","form_type":"4"}},{"id":2718488,"issuer":{"id":4707,"kind":"organization","name":"Replimune Group, Inc."},"owners":[{"id":41714,"kind":"person","name":"Lewis Tanya","position":1,"cik":"0001451038","reported_name":"Lewis Tanya","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Dev. Oper. Off."}}],"security":"Common Stock","published_at":"2021-05-12T01:01:29.000Z","date":"2021-05-10","kind":"grant","acquired":true,"shares":73333,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares of the Issuer's common stock issuable upon settlement of restricted stock units (\"RSUs\") granted to the Reporting Person. Each RSU represents a contingent right to receive one share of the Issuer's common stock. 25% of the RSUs will vest on May 15, 2022 and the remainder will vest in three approximately equal annual installments thereafter until May 15, 2025, subject to the Reporting Person's continuous service to the Issuer."}],"balance_after":73333,"source":{"system":"sec-edgar","filing":"0001104659-21-064730","document":"tm2115949-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1451038/000110465921064730/tm2115949-1_4seq1.xml","form_type":"4"}},{"id":2757609,"issuer":{"id":4707,"kind":"organization","name":"Replimune Group, Inc."},"owners":[{"id":41714,"kind":"person","name":"Lewis Tanya","position":1,"cik":"0001451038","reported_name":"Lewis Tanya","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2021-04-06T00:14:56.000Z","date":"2021-04-01","kind":"grant","acquired":true,"shares":16500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying this option vest entirely on April 1, 2022."}],"balance_after":16500,"derivative":{"exercise_price":31.58,"expiration_date":"2031-04-01","underlying":"Common Stock","underlying_shares":16500},"source":{"system":"sec-edgar","filing":"0001104659-21-046724","document":"tm2112099-6_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1451038/000110465921046724/tm2112099-6_4seq1.xml","form_type":"4"}},{"id":2826214,"issuer":{"id":781,"kind":"organization","name":"Karyopharm Therapeutics Inc.","symbol":"KPTI"},"owners":[{"id":41714,"kind":"person","name":"Lewis Tanya","position":1,"cik":"0001451038","reported_name":"Lewis Tanya","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Reg. Affairs"}}],"security":"Stock Option (right to buy)","published_at":"2021-03-02T01:13:00.000Z","date":"2021-02-25","kind":"grant","acquired":true,"shares":59968,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This option was granted on February 25, 2021 pursuant to the Plan.  The shares underlying this option vest as to 25% of the shares on February 25, 2022, with the remaining 75% vesting in 36 equal monthly installments thereafter."}],"balance_after":59968,"derivative":{"exercise_price":14.56,"expiration_date":"2031-02-24","underlying":"Common Stock","underlying_shares":59968},"source":{"system":"sec-edgar","filing":"0001209191-21-015485","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1451038/000120919121015485/doc4.xml","form_type":"4"}},{"id":2826213,"issuer":{"id":781,"kind":"organization","name":"Karyopharm Therapeutics Inc.","symbol":"KPTI"},"owners":[{"id":41714,"kind":"person","name":"Lewis Tanya","position":1,"cik":"0001451038","reported_name":"Lewis Tanya","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Reg. Affairs"}}],"security":"Common Stock","published_at":"2021-03-02T01:13:00.000Z","date":"2021-02-25","kind":"grant","acquired":true,"shares":22013,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the award of restricted stock units (\"RSUs\") pursuant to the Karyopharm Therapeutics Inc. 2013 Stock Incentive Plan (the \"Plan\"). RSUs convert into Karyopharm Therapeutics Inc. common stock on a one-for-one basis. The RSUs vest in four equal annual installments beginning February 25, 2022."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"The reporting person has reported prior awards of RSUs in Table II of Form 4. The total reported in Column 5 includes the 22,013 newly awarded RSUs, 19,245 RSUs previously reported in Table II, and 4,143 shares of common stock."}],"balance_after":45401,"source":{"system":"sec-edgar","filing":"0001209191-21-015485","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1451038/000120919121015485/doc4.xml","form_type":"4"}},{"id":2854312,"issuer":{"id":781,"kind":"organization","name":"Karyopharm Therapeutics Inc.","symbol":"KPTI"},"owners":[{"id":41714,"kind":"person","name":"Lewis Tanya","position":1,"cik":"0001451038","reported_name":"Lewis Tanya","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Reg. Affairs"}}],"security":"Common Stock","published_at":"2021-02-17T23:49:42.000Z","date":"2021-02-11","kind":"sale","acquired":false,"shares":2046,"price":15.5191,"value":31752.0786,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of restricted stock units and does not represent a discretionary trade by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The sale price of the reporting person's shares represents the weighted average price of all shares sold by a broker on February 11, 2021 on behalf of a group of employees of Karyopharm Therapeutics Inc. to satisfy the payment of withholding tax liability of such employees."}],"balance_after":4143,"source":{"system":"sec-edgar","filing":"0001209191-21-011496","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1451038/000120919121011496/doc4.xml","form_type":"4"}},{"id":2871717,"issuer":{"id":781,"kind":"organization","name":"Karyopharm Therapeutics Inc.","symbol":"KPTI"},"owners":[{"id":41714,"kind":"person","name":"Lewis Tanya","position":1,"cik":"0001451038","reported_name":"Lewis Tanya","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Reg. Affairs"}}],"security":"Restricted Stock Units","published_at":"2021-02-10T01:34:58.000Z","date":"2021-02-05","kind":"exercise","acquired":false,"shares":5650,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Restricted stock units convert into Karyopharm Therapeutics Inc. common stock on a one-for-one basis."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"On February 5, 2020, the reporting person was granted 22,600 restricted stock units, vesting in four equal annual installments beginning on the first anniversary of the grant date.  25% of the restricted stock units vested on February 5, 2021.  Vested shares will be delivered to the reporting person as soon as practicable following the vesting date, but in any event within 30 days of such date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"On February 5, 2020, the reporting person was granted 22,600 restricted stock units, vesting in four equal annual installments beginning on the first anniversary of the grant date.  25% of the restricted stock units vested on February 5, 2021.  Vested shares will be delivered to the reporting person as soon as practicable following the vesting date, but in any event within 30 days of such date."}],"balance_after":16950,"derivative":{"underlying":"Common Stock","underlying_shares":5650},"source":{"system":"sec-edgar","filing":"0001209191-21-009081","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1451038/000120919121009081/doc4.xml","form_type":"4"}},{"id":2871716,"issuer":{"id":781,"kind":"organization","name":"Karyopharm Therapeutics Inc.","symbol":"KPTI"},"owners":[{"id":41714,"kind":"person","name":"Lewis Tanya","position":1,"cik":"0001451038","reported_name":"Lewis Tanya","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Reg. Affairs"}}],"security":"Common Stock","published_at":"2021-02-10T01:34:58.000Z","date":"2021-02-05","kind":"exercise","acquired":true,"shares":5650,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Restricted stock units convert into Karyopharm Therapeutics Inc. common stock on a one-for-one basis."}],"balance_after":6189,"source":{"system":"sec-edgar","filing":"0001209191-21-009081","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1451038/000120919121009081/doc4.xml","form_type":"4"}},{"id":2992649,"issuer":{"id":781,"kind":"organization","name":"Karyopharm Therapeutics Inc.","symbol":"KPTI"},"owners":[{"id":41714,"kind":"person","name":"Lewis Tanya","position":1,"cik":"0001451038","reported_name":"Lewis Tanya","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP,Chief Reg.&Quality Officer"}}],"security":"Restricted Stock Units","published_at":"2020-11-05T01:18:40.000Z","date":"2020-10-28","kind":"exercise","acquired":false,"shares":765,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Restricted stock units convert into Karyopharm Therapeutics Inc. common stock on a one-for-one basis."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"On October 28, 2019, the reporting person was granted 3,060 restricted stock units, vesting in four equal annual installments beginning on the first anniversary of the grant date.  25% of the restricted stock units vested on October 28, 2020.  Vested shares will be delivered to the reporting person as soon as practicable following the vesting date, but in any event within 30 days of such date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"On October 28, 2019, the reporting person was granted 3,060 restricted stock units, vesting in four equal annual installments beginning on the first anniversary of the grant date.  25% of the restricted stock units vested on October 28, 2020.  Vested shares will be delivered to the reporting person as soon as practicable following the vesting date, but in any event within 30 days of such date."}],"balance_after":2295,"derivative":{"underlying":"Common Stock","underlying_shares":765},"source":{"system":"sec-edgar","filing":"0001209191-20-057054","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1451038/000120919120057054/doc4.xml","form_type":"4"}},{"id":2992648,"issuer":{"id":781,"kind":"organization","name":"Karyopharm Therapeutics Inc.","symbol":"KPTI"},"owners":[{"id":41714,"kind":"person","name":"Lewis Tanya","position":1,"cik":"0001451038","reported_name":"Lewis Tanya","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP,Chief Reg.&Quality Officer"}}],"security":"Common Stock","published_at":"2020-11-05T01:18:40.000Z","date":"2020-10-30","kind":"sale","acquired":false,"shares":226,"price":15.58,"value":3521.08,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"This transaction was a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of restricted stock units and does not represent a discretionary trade by the reporting person."}],"balance_after":539,"source":{"system":"sec-edgar","filing":"0001209191-20-057054","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1451038/000120919120057054/doc4.xml","form_type":"4"}},{"id":2992647,"issuer":{"id":781,"kind":"organization","name":"Karyopharm Therapeutics Inc.","symbol":"KPTI"},"owners":[{"id":41714,"kind":"person","name":"Lewis Tanya","position":1,"cik":"0001451038","reported_name":"Lewis Tanya","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP,Chief Reg.&Quality Officer"}}],"security":"Common Stock","published_at":"2020-11-05T01:18:40.000Z","date":"2020-10-28","kind":"exercise","acquired":true,"shares":765,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Restricted stock units convert into Karyopharm Therapeutics Inc. common stock on a one-for-one basis."}],"balance_after":765,"source":{"system":"sec-edgar","filing":"0001209191-20-057054","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1451038/000120919120057054/doc4.xml","form_type":"4"}},{"id":2994722,"issuer":{"id":4707,"kind":"organization","name":"Replimune Group, Inc."},"owners":[{"id":41714,"kind":"person","name":"Lewis Tanya","position":1,"cik":"0001451038","reported_name":"Lewis Tanya","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2020-11-03T21:07:46.000Z","date":"2020-11-02","kind":"grant","acquired":true,"shares":33000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the shares underlying this stock option vest on November 2, 2021, and the remainder of the shares underlying this stock option vest in 24 approximately equal monthly installments thereafter."}],"balance_after":33000,"derivative":{"exercise_price":42,"expiration_date":"2030-11-02","underlying":"Common Stock","underlying_shares":33000},"source":{"system":"sec-edgar","filing":"0001104659-20-120937","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1451038/000110465920120937/a4.xml","form_type":"4"}},{"id":3284411,"issuer":{"id":781,"kind":"organization","name":"Karyopharm Therapeutics Inc.","symbol":"KPTI"},"owners":[{"id":41714,"kind":"person","name":"Lewis Tanya","position":1,"cik":"0001451038","reported_name":"Lewis Tanya","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP,Chief Reg.&Quality Officer"}}],"security":"Restricted Stock Units","published_at":"2020-02-07T21:21:46.000Z","date":"2020-02-05","kind":"grant","acquired":true,"shares":22600,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each restricted stock unit represents a contingent right to receive one share of Karyopharm Therapeutics Inc. common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The restricted stock units vest in four equal annual installments beginning February 5, 2021, the first anniversary of the grant date. Vested shares will be delivered to the reporting person as soon as practicable following each vesting date, but in any event within 30 days of such date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The restricted stock units vest in four equal annual installments beginning February 5, 2021, the first anniversary of the grant date. Vested shares will be delivered to the reporting person as soon as practicable following each vesting date, but in any event within 30 days of such date."}],"balance_after":22600,"derivative":{"underlying":"Common Stock","underlying_shares":22600},"source":{"system":"sec-edgar","filing":"0001209191-20-007515","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1451038/000120919120007515/doc4.xml","form_type":"4"}},{"id":3284410,"issuer":{"id":781,"kind":"organization","name":"Karyopharm Therapeutics Inc.","symbol":"KPTI"},"owners":[{"id":41714,"kind":"person","name":"Lewis Tanya","position":1,"cik":"0001451038","reported_name":"Lewis Tanya","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP,Chief Reg.&Quality Officer"}}],"security":"Stock Option (right to buy)","published_at":"2020-02-07T21:21:46.000Z","date":"2020-02-05","kind":"grant","acquired":true,"shares":60600,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was granted on February 5, 2020.  The shares underlying this option vest as to 25% of the shares on February 5, 2021, with the remaining 75% vesting in 36 equal monthly installments thereafter."}],"balance_after":60600,"derivative":{"exercise_price":18,"expiration_date":"2030-02-04","underlying":"Common Stock","underlying_shares":60600},"source":{"system":"sec-edgar","filing":"0001209191-20-007515","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1451038/000120919120007515/doc4.xml","form_type":"4"}}]}